Top Device Companies

J&J Says Medical Devices 38 Percent Of Sales, Led By Depuy, Ethicon

Johnson & Johnson says its medical-device business now accounts for more than a third of the vast health-care products company’s annual sales. Medical devices and diagnostics are produced by seven companies owned by J&J, and together they account for 43 percent of profits, 38 percent of sales. The leading unit in terms of sales for the first quarter of this year was DePuy with $1.5 billion, followed by Ethicon Endo-Surgery with $1.2 billion, Ethicon at $1.12 billion, andCordis and Vision Care, each with $700 million in sales. (Click here for more)

“Johnson & Johnson Showcases Its Medical Devices” – MedCity News (6/7/10)

Medical device manufacturers facing many challenges: from the rising clout of group purchasing organizations (GPOs) to payment bundling and physicians' growing allegiance with hospitals in product price negotiations. Get all the answers now in new Medtech Insight's new 24-page Special Report: Medical Device Landscape: How regulatory changes and cost control measures are reshaping the industry. Available for purchase now!

J&J’s Cordis Drops Plans To Develop Own Transcatheter Heart Valves

Cordis, a subsidiary of Johnson & Johnson, has decided not to attempt to develop its own replacement heart valves, instead to enter the hot device market by investing in a firm already there. Cordis seeks to use J&J’s venture-capital arm to invest in the market, dropping previous plans to develop its own devices. Cordis Chairman Seth Fischer said the current plan is to form collaborations and partnerships to enter a market already crowded with 40 emerging companies. (Click here for more – a subscription may be required)

“J&J’s Cordis Isn’t Working On Transcatheter Valves Internally” – Wall Street Journal (6/3/10)

Medical device manufacturers facing many challenges: from the rising clout of group purchasing organizations (GPOs) to payment bundling and physicians' growing allegiance with hospitals in product price negotiations. Get all the answers now in new Medtech Insight's new 24-page Special Report: Medical Device Landscape: How regulatory changes and cost control measures are reshaping the industry. Available for purchase now!

Abbott, Boston Sci Lose Bid To Try Cordis, Wyeth Stent Suit In Minnesota

Abbott Laboratories and Boston Scientific lost a bid to have a patent-infringement suit filed by Cordis and Pfizer’s Wyeth tried in a Minnesota federal court. Cordis and Wyeth won their move to have the trial moved to New Jersey where Cordis is headquartered. Cordis, a unit of Johnson & Johnson, and Wyeth sued Abbott, alleging its Xience V stent infringed on the Cordis Cypher stent that had just received a U.S. Patent and Trademark Office patent. Boston Scientific also was named in the suit because it markets the Abbott stent as Xience V under its Promus private label. (Click here for more)

“Cordis And Wyeth Win Transfer Of Stent Dispute With Boston Scientific and Abbott” – Mass Device (1/20/10)

Hot Off the Presses: Medical Device Market 2009: Interventional Cardiology - This 86-page Special Report from IN VIVO identifies the most important trends in cardiology devices in recent years, teases out the critical decisions that drove those developments, and takes you behind the scenes and into the minds of the architects of these new technologies and business strategies. Find out more...

Boston Scientific, J&J Settle 14 Stent Patent Suits In Favor Of J&J

Boston Scientific has agreed to settle 14 patent-infringement suits filed by Johnson & Johnson, with Boston Scientific paying $716.3 million. The suits involve J&J’s Cordis subsidiary, which makes stents for heart-disease patients. Some of the patent suits filed against Boston Scientific were over J&J’s NIR stent-delivery system. With the agreement, J&J is to drop suits it has filed in several countries related to allegations Boston Scientific violated patents on J&J stents and related elements such as balloon catheters, materials and delivery systems. The settlement does not cover several other suits by the two companies, one against the other. (Click here for more)

“Boston Scientific Will Pay J&J $716 Million In Stent Suit” – New York Times (9/29/09)

Medical Device Manufacturers’ Employee Training Programs Are Under FDA Scrutiny -- Click Here To Find Out Why...

Get the week's top medical device news sent directly to you. Sign up for the FREE once-a-week email newsletter from Top Device Companies.com

Boston Scientific Lawyers Allowed To Work Suit Against J&J’s Cordis

A federal court has cleared a law firm to represent Boston Scientific in a suit against Wyeth and Cordis Group even though the firm represents Wyeth in a separate unrelated case in Europe. Wyeth had asked the District Court judge to disqualify Howrey as the plaintiff’s law firm on conflict-of-interest grounds. The judge said the law firm had an “ethical wall” between its lawyers based in Washington, D.C., working on the Boston Scientific case and the lawyers in Europe working on the Wyeth case. Boston Scientific is suing Cordis, a Johnson & Johnson subsidiary, and Wyeth over patent violations for the Promius drug-eluting stent. (Click here for more)

“BoSci’s Lawyers Still On The Job In Stent Patent Suit Vs. Wyeth, Cordis” – Mass Device (8/27/09)

Get the week's top medical device news sent directly to you. Sign up for the FREE once-a-week email newsletter from Top Device Companies.com

Boston Scientific Stents Fare Well In Pair of Studies

Boston Scientific received favorable news from a pair of studies comparing its Taxus and Taxus Express drug-eluting stents with Cordis Group competitors. One of the published studies said the Boston Scientific Taxus stent that elutes pacitaxel compared favorably with the Cordis Cypher stent a year after implantation. Cordis is a unit of Johnson & Johnson. The second study said the Taxus Express stent that elutes the same drug was successful in patients receiving several stents over a two-year period. (Click here for more)

“Studies Deliver Good Results For Boston Scientific’s Taxus” – MassDevice (8/19/09)

Get the week's top medical device news sent directly to you. Sign up for the FREE once-a-week email newsletter from Top Device Companies.com

Boston Scientific, Cordis Propose Settlement Of Stent Dispute To Court

Boston Scientific and Cordis Group have reached a settlement of their dispute over coronary stents and asked a federal court to approve it. The proposal would have Boston Scientific pay $26.1 million in royalties to the Johnson & Johnson unit to cover patent infringements. At issue were Boston Scientific’s Taxus, Liberte, Express and other stents it has marketed since 2007, according to the agreed-upon judgment filed in San Francisco. (Click here for more)

“Boston Scientific To Pay Royalties To Cordis” – Boston Globe (6/17/09)

Get the week's top medical device news sent directly to you. Sign up for the FREE once-a-week email newsletter from Top Device Companies.com

 

PFO Closure: Where Do We Stand?

Article preview reprinted Medtech Insight - May, 2009 

The PFO (patent foramen ovale) closure market has certainly traveled a long and twisted road over the years. And the journey isn't over yet. Although some large companies have pulled back on their US commercialization efforts or decided to exit the field entirely, othrs continue to stick it out, hoping the eventual opportunity will far outweigh the risks and costs involved. In Europe, where percutaneous PFO closure following stroke/TIA is more widely accepted and performed, there are nine CE marked PFO closure devices available from eight different manufacturers, with two more devices expected to be added to the mix in the near future. But despite widespread European acceptance, manufacturers have so far failed to achieve the ultimate goal: US regulatory approval. Find out more...

Article preview reprinted Medtech Insight - May, 2009 

The PFO (patent foramen ovale) closure market has certainly traveled a long and twisted road over the years. And the journey isn't over yet. Although some large companies have pulled back on their US commercialization efforts or decided to exit the field entirely, othrs continue to stick it out, hoping the eventual opportunity will far outweigh the risks and costs involved. In Europe, where percutaneous PFO closure following stroke/TIA is more widely accepted and performed, there are nine CE marked PFO closure devices available from eight different manufacturers, with two more devices expected to be added to the mix in the near future. But despite widespread European acceptance, manufacturers have so far failed to achieve the ultimate goal: US regulatory approval. Find out more...

Long-Term AHRQ/ACC Data Support Drug-Eluting Stent Safety In Elderly

Article preview from "The Gray Sheet" - April 2009

Data from the largest ever long-term observational study of coronary stents in elderly patients show drug-eluting stents are associated with lower rates of death and revascularization than bare-metal stents.

Boston Scientific Ordered To Pay J&J Unit Royalties In Stent Case

Boston Scientific has been ordered by a federal judge to pay Cordis 5.1 percent royalties on sales of Boston Scientific’s guide-wire tubes that allow catheters to slide into place. The U.S. judge in San Francisco ruled that Boston Scientific had infringed on the Johnson & Johnson subsidiary’s patents covering the chemically treated tubes. Cordis had sought a 6 percent royalty in filing the suit, while Boston Scientific argued it should pay only a 0.5 percent royalty. Boston Scientific reported sales of $476 million for its coronary-stent systems last year. (Click here for more)

“Judge Orders Boston Sci To Pay Royalties To J&J” – Minneapolis Star Tribune (4/9/09)

Get the week's top medical device news sent directly to you. Sign up for the FREE once-a-week email newsletter from Top Device Companies.com